Biotechnology News and Research

RSS

Donald Danforth Plant Science Center researchers enter into research collaboration with Dow AgroSciences

Researchers working at the Donald Danforth Plant Science Center have entered into a research collaboration with Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, to study how its EXZACTTM Precision Technology can help improve the root crop cassava for millions of people living in developing countries.

13 Jan 2010

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Spectrum Pharmaceuticals today announced that the second of two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target. The two trials enrolled more than 1600 patients with non-muscle invasive bladder cancer. As per the collaboration agreement with Allergan, a $1.5 million milestone payment will be paid to Spectrum Pharmaceuticals.

13 Jan 2010

Microbix Biosystems signs partnership agreement with Therapure Biopharma

Microbix Biosystems Inc., a biotechnology company focused on virology and biological technologies, and Therapure Biopharma Inc., an integrated biopharmaceutical company that develops, manufactures, purifies and packages therapeutic proteins, announced today the signing of a partnership agreement to manufacture and market water-based products to the pharmaceutical, biotechnology and other industries.

13 Jan 2010

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

Novavax, Inc. announced today that it has successfully completed a pre-clinical safety and efficacy study of its RSV vaccine candidate in cotton rats. Results from this study are needed to support an Investigational New Drug (IND) application to advance this novel recombinant F protein particle based RSV (RSV-F) vaccine candidate into clinical development. This vaccine candidate is composed of recombinant 'F' or 'fusion' protein of RSV which is used by the virus to infect and fuse with cells in the respiratory tract and cause disease.

13 Jan 2010

Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed

Spherix Inc., an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced the completion of patient enrollment in its global Phase 3 clinical trial NEET (70971-004), which is evaluating the safety and efficacy of D-tagatose as an oral treatment for Type 2 diabetes mellitus.

12 Jan 2010

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

TGen Drug Development (TD2) and Critical Outcome Technologies Inc. (COTI) (TSXV:COT) announced today that they will work together to obtain approval of clinical trials for a promising new anti-cancer drug called COTI-2.

12 Jan 2010

Pall acquires U.S. biotechnology company

Pall Corporation, a global leader in filtration, separation and purification, today announced its acquisition of MicroReactor Technologies, Inc. (MRT), a privately held U.S. biotechnology company. MRT has developed a reliable, easy-to-use and cost-effective miniature bioreactor technology platform.

From Pall Corporation 12 Jan 2010

TTI enters into definitive license agreement with Biogen Idec

Trillium Therapeutics Inc. , a biopharmaceutical company developing innovative immune-based biologics, today announced that it has entered into a definitive license agreement with Biogen Idec , granting the latter exclusive worldwide rights to one of Trillium's development programs.

12 Jan 2010

VaxInnate grants license to Biological E. to develop and commercialize recombinant H1N1 vaccine in India

VaxInnate Corporation today announced that it has granted Indian biopharmaceutical company Biological E. Limited a license to its recombinant H1N1 pandemic swine flu vaccine and is collaborating to facilitate the manufacture, clinical development and commercialization of the vaccine in India.

12 Jan 2010

Life Technologies to acquire AcroMetrix

Life Technologies Corporation, a provider of innovative life science solutions, today announced that it has signed a definitive agreement to acquire AcroMetrix, for an undisclosed amount.

12 Jan 2010

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

In recognition of multiple studies connecting ALS to military service, the 2010 Defense Appropriations Act, signed by President Obama on December 22, 2009, provided for the grant of $1.6 million for research and development of potential therapeutics for Amyotrophic Lateral Sclerosis (ALS, Lou Gehrig's disease).

12 Jan 2010

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway’) to those treated with non-evidence-based guidelines (also known as ‘off pathway’), was published in the peer-reviewed Journal of Oncology Practice.

12 Jan 2010

miRagen Therapeutics establishes SAB

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today the formation of the company’s world renowned Scientific Advisory Board (SAB). The SAB was established to provide miRagen with valuable guidance in developing an extensive pipeline of microRNA-based drugs and is comprised of leaders who are internationally recognized experts in their respective fields.

12 Jan 2010

VentiRx Pharmaceuticals completes $25 million Series A Extension

VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) candidates for the treatment of cancer, respiratory and inflammatory diseases, announced today the completion of a $25 million Series A Extension.

12 Jan 2010

Astro Pak announces the launch of new subsidiary, SixLog

Astro Pak Corporation, the U.S.'s largest precision cleaning and passivation company, today announced the launch of their new subsidiary, SixLog Corporation. SixLog provides on-site biological decontamination services utilizing proprietary iHP™ (ionized Hydrogen Peroxide) technology to a variety of industries including Life Sciences, Pharmaceutical, Healthcare, First Responders, Transportation, and Public Facilities.

12 Jan 2010

Madison Williams launches Healthcare Investment Banking and Research business

Madison Williams and Company, an integrated capital markets and advisory firm, announced today the formal launch of a focused Healthcare Investment Banking and Research business. Madison Williams recently completed a management buyout of the principal capital markets business from Sanders Morris Harris Group in December 2009. The new firm already has a leading franchise in the Energy sector, and is quickly establishing its presence in healthcare with key new hires.

12 Jan 2010

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

Georg-August-University Gottingen, University of Regensburg and MRC Technology (MRCT) have signed exclusive license agreements through MBM ScienceBridge GmbH and in agreement with Bayerische Patentallianz GmbH, for the development of a novel therapy of inflammatory and immune diseases based on the depletion of inflammatory monocytes. The first targets will be rheumatoid arthritis (RA) and multiple sclerosis (MS).

12 Jan 2010

Millipore introduces new Viresolve Pro+ Solution

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced the availability of its new Viresolve® Pro+ Solution, an innovative virus filtration product that further extends the company’s leadership in the rapidly growing and highly regulated virus safety market.

12 Jan 2010

QIAGEN N.V. announces acquisition of ESE GmbH for $19 million

QIAGEN N.V. today announced that it has acquired ESE GmbH, a privately held developer and manufacturer of UV and fluorescence optical measurement devices. ESE is based in Stockach, Germany. The transaction is valued at up to US$19 million in cash.

From QIAGEN Manchester Limited 12 Jan 2010

Paragon Biomedical launches second phase of restructuring and growth plan for worldwide operations

Paragon Biomedical, Inc. announced today that it has launched the second phase of its restructuring and growth plan for worldwide operations. Gena Reed, Paragon's Founder and Chief Executive Officer, said the strategy will build upon the company's strengths in its key therapeutic areas and regions.

12 Jan 2010

Biotechnology News and Research

Donald Danforth Plant Science Center researchers enter into research collaboration with Dow AgroSciences

Spectrum Pharmaceuticals achieves its enrollment target in second of two apaziquone Phase 3 trials

Microbix Biosystems signs partnership agreement with Therapure Biopharma

NOVAVAX completes pre-clinical safety and efficacy study of its RSV vaccine candidate

Patient enrollment in Spherix's global Phase 3 clinical trial NEET completed

TD2 and COTI work together to obtain approval of clinical trials for COTI-2

Pall acquires U.S. biotechnology company

TTI enters into definitive license agreement with Biogen Idec

VaxInnate grants license to Biological E. to develop and commercialize recombinant H1N1 vaccine in India

Life Technologies to acquire AcroMetrix

ALS TDI to receive grant of $1.6M for research and development of potential therapeutics for ALS

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

miRagen Therapeutics establishes SAB

VentiRx Pharmaceuticals completes $25 million Series A Extension

Astro Pak announces the launch of new subsidiary, SixLog

Madison Williams launches Healthcare Investment Banking and Research business

MRCT announces licensing deal for development of novel therapy for inflammatory and immune diseases

Millipore introduces new Viresolve Pro+ Solution

QIAGEN N.V. announces acquisition of ESE GmbH for $19 million

Paragon Biomedical launches second phase of restructuring and growth plan for worldwide operations

Biotechnology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News